Global Regulatory Outlook and Regional Trends
Increased R&D productivity in biotech and pharma means more drugs are being evaluated by health authorities and launched in world markets, with 2018 seeing the highest ever number of FDA new drug approvals. Shifting priorities in global pharma pipelines to rare diseases and advances in drug technologies means regulators are evolving guidelines to evaluate more drugs with less data to find meaningful, cost-effective therapies for patients in need. To understand the current landscape, this presentation will examine global and regional trends in:
Complete the form to the right to learn more!